Ocugen Inc
Change company Symbol lookup
Select an option...
OCGN Ocugen Inc
NHEL Natural Health Farm Holdings Inc
ICPT Intercept Pharmaceuticals Inc
BMY Bristol-Myers Squibb Co
DTCFF Defence Therapeutics Inc
STKH Steakholder Foods Ltd
ADBE Adobe Inc
FATP Fat Projects Acquisition Corp
LGVC LAMF Global Ventures I Corp
SECO Secoo Holding Ltd
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.

Price: Delayed
$0.415

Day's Change: 0.015 (3.75%)

Bid: --

Ask: --

B/A Size: --

Day's High: 0.4214

Day's Low: 0.40

Volume (Average) Today's volume of 931,361 shares is on pace to be in-line with OCGN's 10-day average volume of 2,381,997 shares.: 931,361

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.